Then, we also examined differences in pathological scales specific for amyloid (Consortium to establish a registry for Alzheimer's disease [CERAD]) (Mirra et al, 1991) and tau (Braak staging) (Braak & Braak, 1991) pathologies. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.